Etrasimod for Children With Moderately to Severely Active Ulcerative Colitis
Tests etrasimod in young children with moderately to severely active ulcerative colitis.
Plain-language title generated from the registry record
Registry title: A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Key facts
- Where
- Haifa, Jerusalem, Ramat Gan, Rehovot, and Tsrifin, IsraelSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 11 years old?
Source: NCT07470879, who can take part
Where in Israel
- Carmel Medical CenterHaifa, IsraelTaking people
- Rambam Health Care CampusHaifa, IsraelTaking people
- Hadassah medical CenterJerusalem, IsraelTaking people
- Shaare Zedek Medical CenterJerusalem, IsraelTaking people
- Sheba medical centerRamat Gan, IsraelTaking people
- Kaplan Medical CenterRehovot, IsraelTaking people
- Yitzhak Shamir Medical CenterTsrifin, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07470879EU 2025-523100-77-00
- Record updated
- 26 October 2026
- Original description
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).Read full original descriptionShow less
A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Inclusion: Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active Participants are permitted to be receiving a therapeutic dose of select UC therapies.
Exclusion: Severe extensive colitis Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis.